Готові списки джерел за темами / 342.9629 (043.2)

Зміст

Статті в журналах
Звіти організацій

Добірка наукової літератури з теми "342.9629 (043.2)"

Автор: Grafiati

Опубліковано: 30 травня 2022

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "342.9629 (043.2)".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "342.9629 (043.2)"

Borad, Mitesh J., Shantan G. Reddy, Nathan Bahary, et al. "Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer." Journal of Clinical Oncology 33, no. 13 (2015): 1475–81. http://dx.doi.org/10.1200/jco.2014.55.7504.

Повний текст джерела

Анотація:

Purpose TH-302 is an investigational hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. This phase II study (NCT01144455) evaluated gemcitabine plus TH-302 in patients with previously untreated, locally advanced or metastatic pancreatic cancer. Patients and Methods Patients were randomly assigned 1:1:1 to gemcitabine (1,000 mg/m2), gemcitabine plus TH-302 240 mg/m2 (G+T240), or gemcitabine plus TH-302 340 mg/m2 (G+T340). Randomized crossover after progression on gemcitabine was allowed. The primary end point was progression-free surviv

Стилі APA, Harvard, Vancouver, ISO та ін.

Franco, Sandra, Lourdes Mateu, Raquel Pluvinet, et al. "Altered Plasma microRNA Signature in Hospitalized COVID-19 Patients Requiring Oxygen Support." Microorganisms 12, no. 3 (2024): 440. http://dx.doi.org/10.3390/microorganisms12030440.

Повний текст джерела

Анотація:

To discover potential micro(mi)RNA biomarkers of SARS-CoV-2 infection and disease progression, large-scale deep-sequencing analysis of small RNA expression was performed on plasma samples from 40 patients hospitalized for SARS-CoV-2 infection (median 13.50 [IQR 9–24] days since symptoms initiation) and 21 healthy noninfected individuals. A total of 1218 different miRNAs were identified. When compared with healthy noninfected donors, SARS-CoV-2-infected patients showed significantly (fold change [FC] > 1.2 and adjusted p [padj] < 0.05) altered expression of 190 miRNAs. The top-10 differen

Стилі APA, Harvard, Vancouver, ISO та ін.

Marincowitz, Carl, Omar Bouamra, Tim Coates, et al. "1427 The effect of the COVID-19 pandemic on major trauma presentations and patient outcomes in English hospitals." Emergency Medicine Journal 39, no. 12 (2022): A960.2—A964. http://dx.doi.org/10.1136/emermed-2022-rcem2.2.

Повний текст джерела

Анотація:

Aims, Objectives and BackgroundThere is evidence that COVID-19 ‘lockdowns’ may have contributed to increased non-accidental injury, domestic violence and self-harm related to deteriorating mental health. Internationally, there is also evidence that the diversion of health care resources may led to worse outcomes for patients presenting with major trauma. There has been no previous national evaluation of ‘lockdown’ measures impact on the characteristics, treatment pathways and outcomes of trauma patients in EnglandWe aimed to assess the impact of successive lockdowns on the volume, demographics

Стилі APA, Harvard, Vancouver, ISO та ін.

Fujii, Hisaki, Kevin She, Soudabeh Aslanian, et al. "Inflammatory Markers and Autoantibodies That Correlate with Early and Late Onset of New Onset Pediatric Chronic Graft-Versus-Host Disease (GVHD)." Blood 108, no. 11 (2006): 3232. http://dx.doi.org/10.1182/blood.v108.11.3232.3232.

Повний текст джерела

Анотація:

Abstract Chronic graft-vs-host disease (cGVHD) has previously been characterized by elevation of a number of inflammatory markers and autoantibodies. We hypothesized that evaluation of such markers would contribute to a biological classification of new onset cGVHD in children and possibly aid in early diagnosis. The COG study ASCT0031 is a phase III cGVHD therapeutic trial that included the biological evaluation of 52 newly diagnosed cGVHD pts and 34 time-matched post BMT control patients (2 – 18 yrs) with no clinical evidence of cGVHD. Chronic GVHD was divided into an early onset between 3 to

Стилі APA, Harvard, Vancouver, ISO та ін.

He, Xin, Kyriakie Sarafoglou, Patricia Y. Fechner, et al. "Changes in Adrenal and Gonadal Androgens After 14-Day Treatment With CRF1 Receptor Antagonist, Crinecerfont (NBI-74788), in Men With Classic 21-Hydroxylase Deficiency." Journal of the Endocrine Society 5, Supplement_1 (2021): A78. http://dx.doi.org/10.1210/jendso/bvab048.157.

Повний текст джерела

Анотація:

Abstract Background: Congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency (21OHD) causes cortisol insufficiency and androgen excess. A phase 2 trial of crinecerfont, a CRF1 receptor antagonist, in 18 adults with 21OHD showed prominent decreases in ACTH, 17-hydroxyprogesterone, and androstenedione (A4), and in women, testosterone (T), after 14 days of treatment. In men with 21OHD, T derives from both adrenals and testes; in poor disease control, A4/T ratio is elevated due to disproportionately increased adrenal A4 production and decreased testicular T production. We sought to

Стилі APA, Harvard, Vancouver, ISO та ін.

Suttorp, Meinolf, Ralf Knoefler, Hélène Deutsch, et al. "High Platelet Counts, Thrombosis, Bleeding Signs, and Acquired Von Willebrand Syndrome at Diagnosis of Pediatric Chronic Myeloid Leukemia." Blood 134, Supplement_1 (2019): 4152. http://dx.doi.org/10.1182/blood-2019-123343.

Повний текст джерела

Анотація:

Background: At diagnosis of chronic myeloid leukemia (CML) patients (pats) may present with elevated platelets (PLT) counts. Generally, high PLT counts may result in thrombosis and/or bleeding complications, the latter being due to binding of von Willebrand factor (VWF) multimers to platelets. Pediatric CML is very rare (Hijiya N, Suttorp M 2019; Blood 33:2374-2384) and no systematic investigation on clinical complications of elevated PLT counts has so far been reported. Methods: Data on PLT counts and associated thrombo-hemorrhagic complications were retrospectively analyzed in newly diagnose

Стилі APA, Harvard, Vancouver, ISO та ін.

Siddiqui, S. H., N. Kumari, and N. Krishnani. "Histopathological Spectrum in Pancreaticoduodenectomy Specimens: Fifteen Year Study from a Tertiary Care Centre in North India." American Journal of Clinical Pathology 154, Supplement_1 (2020): S60. http://dx.doi.org/10.1093/ajcp/aqaa161.129.

Повний текст джерела

Анотація:

Abstract Introduction/Objective The periampullary region is histologically complex owing to the confluence of three different kinds of epithelia (duodenal, pancreatic, biliary) harbouring four types of cancers. Although anatomical proximity warrants a common surgical approach, overall survival depends largely on the type of surgical indication. Malignant epithelial tumors are the predominant indications, accompanied by a myriad of benign tumors and tumor-like lesions. We reviewed our archival pancreaticoduodenectomies to analyze the spectrum of these lesions. Methods All pancreaticoduodenectom

Стилі APA, Harvard, Vancouver, ISO та ін.

Dombret, Hervé, Alexandra Coelho, Laurène Fenwarth, et al. "Treatments and Outcomes of Adult Patients with AML in the Real-Life - First Report of the French Observational ALFA-PPP Study." Blood 144, Supplement 1 (2024): 2424. https://doi.org/10.1182/blood-2024-207226.

Повний текст джерела

Анотація:

Introduction. AML treatment options have been recently enriched. New agents like gemtuzumab ozogamicin (GO), FLT3 or IDH inhibitors, or CPX-351 have been approved for some patient subsets. Less-intensive options, like the AZA-VEN combination, are used in older/unfit patients. However, while treatments and indications are standardized, their choice is not, depending on often-subjective factors. This makes observational studies so important to describe the real-life management and outcomes of AML patients. Methods. In 2022, the ALFA group initiated a 2-cohort (newly diagnosed, relapsed/refractor

Стилі APA, Harvard, Vancouver, ISO та ін.

Ishibashi, Toshihiro. "Can Transcranial Ultrasonication Increase Recanalization Flow Ratio with Tissue Plasminogen Activator?" Stroke 32, suppl_1 (2001): 360. http://dx.doi.org/10.1161/str.32.suppl_1.360-d.

Повний текст джерела

Анотація:

P119 Purpose: The enhancement by a newly developed method of transcranial ultrasonication (TU) of thrombolysis with tissue plasminogen activator (TPA) was investigated in acute ischemic stroke (AIS) with an in vivo rabbit femoral artery occlusion model. Method: The femoral arteries of 36 rabbits were exposed, and stenosis was produced with 5–0 silk suture to reduce the flow to 77.3±6.9%. Poststenotic flow was measured with a flow meter at proximal segments of the femoral artery. Thrombosis was achieved by injecting thrombin through the cannulated branching artery into a 1-cm segment proximal t

Стилі APA, Harvard, Vancouver, ISO та ін.

Magrey, M., M. G. H. Van de Sande, M. Breban, et al. "POS1107 BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 876–77. http://dx.doi.org/10.1136/annrheumdis-2023-eular.836.

Повний текст джерела

Анотація:

BackgroundIn patients (pts) with axial spondyloarthritis (axSpA), tumour necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience loss of response over time, and some are intolerant to TNFis.[1]Typically, response to second line biologics is limited in TNFi-inadequate responders (IR).Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In the phase 3 BE MOBILE 1 and 2 studies, BKZ treatment resulted in rapid and sustained improvements in efficacy outcomes through 52 weeks (wks) in pts with acti

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Звіти організацій з теми "342.9629 (043.2)"

เตชะกำพุ, มงคล, วันเพ็ญ อดุลยานุภาพ та จินดา สิงห์ลอ. การแช่เย็นและการแช่แข็งตัวอ่อนสุกร : รายงานผลการวิจัย. จุฬาลงกรณ์มหาวิทยาลัย, 1998. https://doi.org/10.58837/chula.res.1998.56.

Повний текст джерела

Анотація:

ศึกษาความเป็นไปได้ในการแช่เย็นและแช่แข็งตัวอ่อนสุกร โดยเก็บตัวอ่อนอายุ 7 วันจากสุกรสาวหลังกระตุ้นด้วยฮอร์โมน เพรกแนนท์ แมร์ ซีรั่ม โกนาโดโทรปิน และฮิวแมน โคริโอนิกโกนาโดโทรปิน ในอัตราส่วน 400:200 ไอยู แบ่งเป็น 4 การทดลอง คือ การทดลองที่ 1 แช่เย็นตัวอ่อนระยะ morula, early blastocyst, blastocyst และ expanded blastocyst จำนวน 48 ตัวอ่อน ที่อุณหภูมิ 4 องศาเซลเซียส ในน้ำยา TCM199 2.5 Hepes+10%DMSO นาน 1, 6, 12 และ 24 ชม. ผลปรากฏว่าหลังเลี้ยงนาน 24 ชม. ไม่มีตัวอ่อนใดรอดเลยหลังจากเก็บไว้ การทดลองที่ 2 แช่แข็งตัวอ่อนระยะ blastocyst และ expanded blastocyst จำนวน 69 ตัวอ่อนแบบใช้ลดอุณหภูมิช้าๆ โดยลดอุณห

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!